Axsome Therapeutics Inc
AXSM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.43B
Close$
$23.38
83.5% downside
Current Fair Value
83.5% downsideOvervalued by 83.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.43 Billion |
|---|---|
| Enterprise Value | $7.33 Billion |
| Earnings per Share | $-3.68 |
| Beta | 0.6 |
| Outstanding Shares | 52,445,193 |
Return
| Return on Equity | -149.19% |
|---|---|
| Return on Assets | -19.02% |
| Return on Invested Capital | -48.39% |
Valuation & Multiples
| P/E Ratio | -46.3 |
|---|---|
| PEG | 63.66 |
| Price to Sales | 8.86 |
| Price to Book Ratio | 70.85 |
| Enterprise Value to Revenue | 8.48 |
| Enterprise Value to EBIT | -47.81 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 2.07 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 9, 2026
EPS Estimate
-$0.42
Consensus analyst estimateRevenue Estimate
$259.21 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 22, 2027
EPS Estimate
-$0.05
Consensus analyst estimateRevenue Estimate
$284.03 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.62, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.6154▼ 48.78% |
|---|---|
| Total Calls | 1,300▼ 99.85% |
| Total Puts | 800▼ 99.92% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.94%▼ 67.36% |
|---|---|
| Total Invested | $753.71M▼ 92.00% |
| Investors Holding | 188▼ 354.00% |
About Axsome Therapeutics Inc
712 employees
CEO: Herriot Tabuteau
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...